190 results about "Cells transplantation" patented technology

A method of determining the voltage and current output required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage in the treatment of osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffolds, growth factors, etc.) for treating cartilage defects in the human knee joint and a device for delivering such signals to a patient's knee. An analytical model of the human knee is developed whereby the total tissue volume in the human knee may be determined for comparison to the total tissue volume of the diseased tissue in the animal model using electric field and current density histograms. The voltage and current output used in the animal model is scaled based on the ratio of the total tissue volume of the diseased tissue of the human to the total tissue volume of the diseased tissue in the animal model and the resulting field is applied to the diseased tissue of the human using at least two electrodes applied to the knee or a coil or solenoid placed around the knee. The voltage of the signal applied to the electrodes, coil or solenoid is varied based on the size of the knee joint; larger knee joints require larger voltages to generate the effective electric field.

An improved method of nuclear transfer involving the transplantation of donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation.

The invention belongs to the field of allogenic mesenchymal stem cells, and particularly relates to a preparation method of allogenic mesenchymal stem cells by CRISPR (clustered regularly interspaced short palindromic repeats) technique editing and IGF (insulin-like growth factor) optimization and application of the allogenic mesenchymal stem cells in treating myocardial infarction. The preparation method comprises the following steps: carrying out separation by density gradient centrifugation to obtain allogenic single karyocytes, and carrying out adherent culture to obtain mesenchymal stem cells; designing a mesenchymal stem cell surface antigen B2M-gRNA and an inflammatory factor TNF-alpha-gRNA; establishing recombinant slow virus particles, and transfecting the mesenchymal stem cells; optimizing the mesenchymal stem cells by using IGF-1; and preparing drugs for treating myocardial infarctions by using the modified and optimized mesenchymal stem cells. The CRISPR/Cas9 technique is utilized to remove the antigens capable of causing immunological rejection and the inflammatory factors capable of causing inflammatory reaction on the mesenchymal stem cell surface, and the IGF-1 is utilized to enhance the apoptosis resistance of the mesenchymal stem cells and promote the homing of the mesenchymal stem cells, thereby providing a new technical scheme for preparing drugs for treating cardiovascular diseases in clinic. The prepared allogenic mesenchymal stem cells can not cause immunological rejection after cell transplantation.

A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D.

The present invention provides for a method for tissue engineering by cell implantation that involves the use of a scaffold in situ at the site of a defect, where the therapeutic cells are fixed in place into the scaffold only once the scaffold is inserted at the site of the tissue defect, thereby locking not only the cells to the scaffold, but also the scaffold to the tissue defect. The invention also provides a kit of parts suitable for performing the method of the invention.

The invention relates to the field of biotechnology and provides a method for long-time in-vitro culturing and proliferating hepatic cells. The method includes that mature hepatic parenchymal cells are induced to be hepatic cells with infinite proliferation capability in vitro. The hepatic cells obtained by the method can be used for toxicological and pharmacological evaluation of compounds and drug, study and diagnosis as well as treatment of hepatitis virus, hepatic cell transplantation therapy and preparation of bioartificial liver.

An endoscopic method for treating cartilage or bone defects in an animal, said method comprising the steps of: I) identifying the position of the defect, ii) applying cells selected from the group consisting of chondrocytes, chondroblasts, osteocytes and osteoblasts and combinations thereof into the cartilage or bone defect. In particular, the invention relates to a method for arthroscopic or endoscopic implantation of homologous or autologous cells into a defect of an animal body, the method comprising a step of I) arthroscopic or endoscopic application of a fluid to a cavity or surface containing the defect, and the steps of ii) application of the cells to the defect substantially simultaneously with a support material, the application being performed at the defect covered by the fluid, iii) mixing of the cells and the supporting material, iv) solidification of the supporting material so that the defect is covered by a mixture of cells and support material without any significant amount of fluid, and v) optionally, removal of the fluid from the cavity or surface by drainage or suction.

The invention relates to a bioactive substance included alginate microcapsule product. The invention is characterized in that: the microcapsule product is a spherical microcapsule with diameter of 100 to 1,000 microns, and the structure of the microcapsule product comprises a microcapsule film and a core, wherein the microcapsule film is a polyelectrolyte composite hydrogel film formed by electrostatic complexing reaction of two macromolecular materials, namely alginate and epsilon-polylysine; and the core is a liquid or hydrogel environment containing a bioactive substance. The microcapsule product is mainly applied to cell transplantation, cell culture and included carriers of bioactive substances such as protein, polypeptide, enzyme, nucleic acid and the like.

The invention discloses an application of umbilical cord mesenchymal stem cells (MSCs) in the acute myocardial infarction cell transplantation therapy; the application is suitable for ST-segment elevation acute myocardial infarction within one mouth or non ST-segment elevation acute myocardial infarction cases, a vascular remodeling is carried out to a patient who is attacked by the disease withinsix hours, after about four to six days, coronary perfusion is carried out to the patient; and the other patients who choose date to carry out vascular remodeling operation, the coronary perfusion iscarried out at the same time. The treating effect in the invention is superior to the bone mesenchymal stem cells transplantation.

A method for the preparation of dermal papilla tissue comprising the step of culturing mesenchymal stem cells in a medium having a specific composition is provided. The method makes it possible to form in vitro a quantity of dermal papilla tissues having hair follicle inducting ability and, accordingly, it can be effectively used for the treatment of alopecia through cell transplantation.

The invention provides a method for inducing mesenchymal stem cell in the bone marrow to obtain the nerve prosoma cell, which comprises the following steps: doing generation culture for the separated and purified mesenchymal stem cell in the bone marrow, switching stable generation mesenchymal stem cell into induction culture medium, inducing and culturing for 7-20 d, obtaining nerve prosoma cell. The induction culture medium is basic culture medium which is charged with growth factor, wherein the growth factor mainly comprises an epiderm growth factor (EGF), a base fibroblast growth factor (bFGF), an insulin growth factor-1 (IGF-1) and a nerve nourishment factor 3 (NT-3). The invention provides a method for inducing mesenchymal stem cell in the bone marrow to obtain the nerve prosoma cell which can be differentiated into nerve cell and the nerve prosoma cell can be switched into inner ear hair cell and inner ear supporting cells, which provides experiment evidence for cochlear cell transplantation therapeutic sound perception nerve deafness and solves the problem of the transplantation cell resource.

Disclosed are: a composition for organ, tissue or cell transplantation, containing, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1, a peptide having at least 80% sequence homology with the amino acid sequence, or a peptide which is a fragment thereof; a kit comprising the composition; or a method using the composition. By using the composition, the kit, or the method, the viability and/or function of an organ, tissue, or cell after transplantation are strengthened and an organ, tissue or cell isolated from a living body is preserved temporarily without damage.

A cell culture support is first prepared that is coated on a surface with a polymer the hydration force of which changes in a temperature range of 0-80° C.; cancer cells are then cultivated on the support in a temperature region where the polymer has weak hydration force; thereafter, the culture solution is adjusted to a temperature at which the polymer has a stronger hydration force, whereby the cultured cancer cells are detached; the detached cancer cells are then transplanted to a specified site of an animal on which transplantation is to be performed; this method is an efficient way of cancer cells transplantation.

The invention relates to an alginate-chitosan microcapsule modified via in situ covalent PEG grafting. The structure of the microcapsule is divided into two parts, i.e., a microcapsule membrane and an inner core, wherein the microcapsule membrane is a polyelectrolyte composite hydrogel membrane formed by chitosan and alginate, the surface of the membrane is modified via in situ covalent PEG grafting, and the inner core is an alginate liquid or alginate hydrogel environment containing living cells. Because of resistance to protein adsorption, the microcapsule is applied to living cell encapsulation and used as an immunoisolation carrier for cell transplantation.

The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14⁺ monocyte, with a unique phenotype of CD14⁺CD45⁺CD34⁺ type I collagen⁺. These cells have a potential to differentiate into mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, and neurons under particular culture conditions.

Cell transplantation for constructing biological heart pacemaker is used embryo source dry/ancestral cell and adult mesogalia dry cell as cell sources. The process is carried out by oriented differentiation inducing for heart pacemaker cell by embryo source multifunctional dry cell, bone marrow adhering to obtain primary culture cell, clone culturing to obtain purifying system by diluting, applying paracrine factor endothelin-1 or nervous adjusting protein-1, extracellular matrix laminated adherent protein and fiber connecting protein etc. substrate glue, trans-dyeing pacemaker gene HCN4, and in-vitro inducing embryo source multifunctional dry cell. It is various and non-immunogenicity. It can be used to treat sick sinus syndrome.

The invention relates to a mesenchymal stem cell of marrow, umbilical cord or bleeding of the umbilicus and purpose in the field of cell transplantation, stem cell culture, expansion and oriented differentiation. The mesenchymal stem cell for expressing a related gene of a neurotrophin family is prepared by the following steps of extracting a mesenchymal stem cell from the marrow, the umbilical cord or the bleeding of the umbilicus; recombining the related gene of the neurotrophin family to an AAV (Adeno-Associated Virus) used as a carrier; preparing the AAV expressing the related gene of the neurotrophin family; and infecting separated and purified mesenchymal stem cell through AAV particles to obtain the mesenchymal stem cell expressing the related gene of the neurotrophin family. The invention is used as a culture layer cell to provide a manually controlled microenvironment for stem cell culture, expansion and oriented differentiation and promote the proliferation and the oriented differentiation of the stem cells so as to provide a new curing measure for human diseases.